Long-term efficacy and safety of solifenacin, mirabegron, and their combination for overactive bladder: a systematic review
BackgroundCurrent clinical guidelines recommend either muscarinic receptor antagonists or β3-adrenoceptor agonists for overactive bladder (OAB) treatment. These recommendations, however, are primarily based on short-term (12-week) clinical trials, leaving a critical gap in evidence regarding their l...
Αποθηκεύτηκε σε:
| Κύριοι συγγραφείς: | , , , |
|---|---|
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Frontiers Media S.A.
2026-06-01
|
| Σειρά: | Frontiers in Pharmacology |
| Θέματα: | |
| Διαθέσιμο Online: | https://www.frontiersin.org/articles/10.3389/fphar.2026.1874436/full |
| Ετικέτες: |
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|